Actively Recruiting

Age: 65Years +
All Genders
NCT07277361

Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment

Led by Wladimir MAUHIN, Dr · Updated on 2025-12-11

100

Participants Needed

1

Research Sites

366 weeks

Total Duration

On this page

Sponsors

W

Wladimir MAUHIN, Dr

Lead Sponsor

U

University Hospital, Angers

Collaborating Sponsor

AI-Summary

What this Trial Is About

Fabry disease is a rare genetic disorder affecting 1 in 10,000 individuals, leading to complications such as chronic pain, heart and kidney failure, and strokes, ultimately impacting life expectancy. People with this disease are increasingly being diagnosed later in life, around the age of 65, as the condition progresses slowly with irreversible organ damage. The effectiveness of treatments for Fabry disease remains controversial, but early initiation is recommended for long-term benefits. Despite the high cost and inconvenience of treatments, there is limited research on their efficacy in older people or on the quality of life for those aged 65 and over with Fabry disease. This study aims to assess the quality of life in this age group both with and without treatment over a period of 5 years to determine the benefits of treatment beyond the age of 65.

CONDITIONS

Official Title

Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 65 and over diagnosed with Fabry disease
  • For men: proven alpha-galactosidase A deficiency or identified pathogenic GLA genetic variant
  • For women: identified pathogenic GLA genetic variant
  • Available minimum work-up including ECG, 24h holter ECG, cardiac ultrasound, creatinemia, proteinuria and/or microalbuminuria
  • Have received written and oral information about the study and have not opposed participation
  • Affiliated with a social security scheme or entitled to benefits (excluding AME)
Not Eligible

You will not qualify if you...

  • Inability to understand the information provided about the study
  • Under guardianship, curatorship, or safeguard of justice
  • Under restraint or deprived of liberty by judicial or administrative decision

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Groupe Hospitalier Diaconesses Croix Saint-Simon

Paris, France, France, 75020

Actively Recruiting

Loading map...

Research Team

D

Djazia Bouzelmat, Clinical Research Assistant

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here